With Added Organic Compound Patents (Class 424/629)
  • Patent number: 9492374
    Abstract: There is provided pharmaceutical compositions suitable for the treatment of infected ulcers in mammals, such as diabetes related ulcers and varicose ulcers. Said compositions comprise vancomycin, gentamicin, amikacin, fluconazole, ciprofloxacin and metronidazole or its corresponding salts and an hypertonic amount of sodium chloride in a suitable polar and aprotic or protic acidic as pharmaceutical carrier. There is further disclosed a methods for treating ulcers in mammals using the disclosed compositions.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: November 15, 2016
    Inventor: Jose Rafael Salinas Andrade
  • Patent number: 9028878
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 12, 2015
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Publication number: 20150086643
    Abstract: A traditional Chinese medicine compound antitumor nano preparation, comprising the following components by weight percentage: 28%-32% of solid lipid nanoparticles containing volatile oil of frankincense and myrrh, 61%-65% of nano realgar carrying microcapsule, 0.8%-1.3% of bezoar micro-powder and 4%-6% of musk micro-powder. Use of the above traditional Chinese medicine compound antitumor nano preparation for preparing antitumor drugs. The traditional Chinese medicine compound antitumor nano preparation of the present invention can remarkably improve bioavailability of every component in the traditional Chinese medicine compound; at the same time, it can achieve better curative effect with reduced dosage.
    Type: Application
    Filed: February 13, 2014
    Publication date: March 26, 2015
    Inventors: Nianping Feng, Feng Shi, Ying Liu, Jihui Zhao, Yongtai Zhang
  • Patent number: 8974915
    Abstract: PU/ZnO nanocomposites are provided wherein the addition of less than 1 vol % 33 nm ZnO nanoparticles into a PU matrix effect a decrease in the Young's Modulus and storage modulus of the polymer, while simultaneously effecting an increase glass transition temperature of the polymer. Detailed experiments are described (e.g., FTIR, DMTA, FESEM and AFM) that suggest that the reaction between hydroxyl groups of the ZnO nanoparticles and isocyanate groups of the polyurethane prepolymer disrupts the self-assembly of the phase separation in PU. Phase separation is responsible for the good mechanical properties of PU. Further, detailed experiments suggest that the increase of the glass transition temperature results from the crosslinking effect of the ZnO nanoparticles.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: March 10, 2015
    Assignee: Rensselaer Polytechnic Institute
    Inventors: Junrong Zheng, Rahmi Ozisik, Richard W. Siegel
  • Publication number: 20140227221
    Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.
    Type: Application
    Filed: December 4, 2013
    Publication date: August 14, 2014
    Applicant: Prolexys Pharmaceuticals, Inc.
    Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
  • Patent number: 8389021
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: March 5, 2013
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Publication number: 20120195974
    Abstract: The invention disclosed in this document concerns controlling mealybugs.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Mayank Yadav, Suresh Ramachandran, Sanjoy Kundu
  • Publication number: 20120070511
    Abstract: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.
    Type: Application
    Filed: September 21, 2011
    Publication date: March 22, 2012
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Theodore Lampidis, Metin Kurtoglu
  • Publication number: 20110123486
    Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.
    Type: Application
    Filed: June 25, 2008
    Publication date: May 26, 2011
    Applicant: Prolexys Pharmaceuticals, Inc.
    Inventors: Paul B Robbins, Sudhir R. Sahasrabudhe
  • Publication number: 20110110885
    Abstract: Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are compounds according to Formulas I-IV, pharmaceutical compositions, unit dosage forms, and food or feed supplements containing such compounds.
    Type: Application
    Filed: July 31, 2007
    Publication date: May 12, 2011
    Inventors: Jeanine D'Armiento, Kurt Reynertson, Edward Kennelly, Alison Wallace
  • Publication number: 20100316566
    Abstract: The present invention concerns methods and compositions related to a chelator and a HHRT ligand. In specific embodiments of the invention the chelator is conjugated to the HHRT ligand. In another specific embodiment of the invention, the chelator is chelated to a metal. In a particular embodiment of the invention, there is a metal species that is chelated to a chelator, which is then directly or indirectly conjugated to a HHRT ligand. In some embodiments, the composition further comprises a therapeutic agent. In particular cases, the compositions are employed for cancer diagnosis and/or therapy.
    Type: Application
    Filed: February 27, 2009
    Publication date: December 16, 2010
    Applicant: RADIOMEDIX INC.
    Inventors: Jennifer Sims-Mourtada, Ali Azhdarinia, Izabela Tworowska, Hitomi Saso
  • Patent number: 7619000
    Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: November 17, 2009
    Assignees: The Texas A&M University System, Board of Regents, The University of Texas System
    Inventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
  • Patent number: 7563461
    Abstract: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, or by various physical, chemical, mechanical, or biological irritants, including infectious agents.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: July 21, 2009
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Shanta M. Modak, Trupti Gaonkar, Milind Shintre, Lauserpina Caraos, Ingrid Geraldo
  • Patent number: 7205001
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Polarx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7179493
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: February 20, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7163703
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: January 16, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 7060656
    Abstract: An antibacterial rockwool growth medium for hydroponics is used for hydroponic growth of rice, flowers and ornamental plants, fruitage, etc. The medium includes a rockwool base used as a culture medium for hydroponics, and an inorganic antibacterial agent is dispersed substantially uniformly onto an overall surface of the rockwool base or a part of the surface of the rockwool base.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: June 13, 2006
    Assignee: Akechi Ceramics Kabushiki Kaisha
    Inventors: Yoshinari Kato, Satoshi Kameshima
  • Patent number: 6995188
    Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: February 7, 2006
    Assignees: Board of Regents, The University of Texas System, The Texas A&M University System
    Inventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
  • Patent number: 6939566
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: September 6, 2005
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 6911471
    Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: June 28, 2005
    Assignees: The Texas A&M University System, Board of Regents, The University of Texas System
    Inventors: Ralph A. Zingaro, Emil J. Freireich, Hatice Duzkale, Hagop Kantarjian, Srdan Verstovsek, Merida Sotelo-Lerma
  • Patent number: 6875451
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: April 5, 2005
    Assignee: PolaRx Biopharmaceuticals Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 6861075
    Abstract: A storage-stable biocidal aerated gel composition comprises from 30 to 97% by weight of water, from 0.2 to 5% by weight of a gelling agent selected from xanthan gum, sodium alginate and neutralised carboxyvinyl polymer from 2 to 5% by weight of a fine particulate, hydrophobic silicone-treated silica having a surface area of from 80 to 300 m2/g and from 0.004 to 20% by weight of a biocide which said composition is in the form of fine particles of an aqueous gel containing the water, gelling agent and the biocide, the surfaces of which fine particles are coated with a coating of the finely particulate hydrophobic silica. The biocidal aerated gel composition can be used to control pests using one or more appropriate biocides in the composition.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: March 1, 2005
    Assignee: Sorex Limited
    Inventor: Roland S. Twydell
  • Patent number: 6764692
    Abstract: A method of treating laminitis in a horse is disclosed, comprising administering to the horse a naturally chelated trace mineral composition; promoting healthy skin, hair and hoof tissue. A method of reducing dietary intake is also disclosed, comprising administering to a horse in need thereof, effective amounts of a naturally chelated trace mineral composition. A method of preparing the chelated trace mineral composition from ocean seabed rock is further disclosed, as well as the chelated trace mineral composition.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: July 20, 2004
    Inventor: Carlos Cortelezzi
  • Patent number: 6733798
    Abstract: The present invention includes a cranberry seed oil, a cranberry flour and a method for making cranberry seed oil and flour. The cranberry seed oil comprises beta sitosterol and phosphatidylcholine.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: May 11, 2004
    Inventors: Tim Heeg, Bernard G. Lager, II
  • Publication number: 20040028750
    Abstract: The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).
    Type: Application
    Filed: August 7, 2003
    Publication date: February 12, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventor: Daopei Lu
  • Patent number: 6630172
    Abstract: Disinfectant formulations are described which are preferably ecologically friendly and non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having at least one metal ion which is microbicidal to at least one microorganism and potassium sodium tartrate in some form. When potassium sodium tartrate is used with these metal ions, it enhances the complex-forming properties of such metal complexes while concurrently increases their efficacy and potency at the same level of metal ion concentrations. These microbicidal formulations can be diluted in suitable proportions into aqueous systems to produce the desired dosages for each individual case, depending on the level and the severity of the contamination. The microbicidal formulations can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: October 7, 2003
    Inventor: Kareem I. Batarseh
  • Patent number: 6521265
    Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: February 18, 2003
    Assignee: Biolife, L.L.C.
    Inventor: James A. Patterson
  • Patent number: 6413551
    Abstract: A termiticide which comprises at least one compound which in the presence of a termite produces a termiticidally effective amount of hydrogen sulfide.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: July 2, 2002
    Inventor: David William Holloway
  • Publication number: 20020054919
    Abstract: Novel compositions and methods for reducing odor. The composition comprises at least one synthetic zeolite, at least one acid and at least one substance selected from a metal oxide, metal, or salt of a metal or metal oxide. A wide range of odors, including ammonia and sulfurous odors, may be controlled by contacting an effective amount of the above composition with the article, substance or environment that emits the undesired odor. The composition may also be incorporated into other substances for odor reduction or control to form odor-controlled articles.
    Type: Application
    Filed: September 6, 2001
    Publication date: May 9, 2002
    Inventors: Mark A. Hochwalt, Michael L. Trehy
  • Patent number: 6242009
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: June 5, 2001
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 5985335
    Abstract: The invention relates to an agent for the prophylaxis and/or therapy of conditions associated with a disorder of bone formation. It contains alkali metal citrates and/or alkali metal lactates and/or alkali metal malates, optionally together with one or more active substances selected from vitamin K, calcium salts and vitamin D. The agent preferably contains potassium citrates and/or sodium citrates or potassium lactates and/or sodium lactates and serves for the prophylaxis and/or therapy of osteoclasis, in particular osteoporosis or osteomalacia.
    Type: Grant
    Filed: November 28, 1997
    Date of Patent: November 16, 1999
    Assignee: Orthomol Pharmazeutische Vertriebs GmbH
    Inventor: Hans Dietl
  • Patent number: 5709890
    Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: January 20, 1998
    Assignee: Donlar Corporation
    Inventor: J. Larry Sanders
  • Patent number: 5198230
    Abstract: This invention provides a recipe for making a detoxification medicine named DTS (Deities) for curing drug addiction. This DTS (Deities) medicine comprises no narcotic but mainly is made up by several kinds of effective ingredients of biological substances refined from various natural herbs and bioproducts. Drug addicts can be weaned and cured safely from addiction induced by Heroin, Cocaine, Morphine, Amphetamines, Hemp or Opium, and other substances within 7-30 days, by means of DTS (Deities) which can get rid of drug poisons present in an addict's blood and marrow. Further, DTS (Deities) can also be used to clear away tobacco tar and nicotine deposits so that it serves to wean from cigarette smoking as well.
    Type: Grant
    Filed: January 8, 1991
    Date of Patent: March 30, 1993
    Inventor: Liu C. Wen